多发性硬化症治疗靶点的识别与新进展——聚焦于克拉屈滨
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
作者信息
Warnke Clemens, Wiendl Heinz, Hartung Hans-Peter, Stüve Olaf, Kieseier Bernd C
机构信息
Department of Neurology, Heinrich-Heine University Düsseldorf, Germany.
出版信息
Drug Des Devel Ther. 2010 Jul 21;4:117-26. doi: 10.2147/dddt.s6627.
Abstract
Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been published. However, benefits need to be weighed against the risks to define the role of these compounds within current treatment regimens. In this review, data on the efficacy of a promising compound, oral cladribine, are discussed and balanced with known and anticipated risks in a postmarketing era, and finally gives an outlook on the potential place of this drug in treatment algorithms for MS in the future.
摘要
用于复发缓解型多发性硬化症（MS）的口服疾病修正药物是这种慢性致残性疾病尚未满足的需求。在目前处于3期临床阶段的5种正在研究的药物中，芬戈莫德和口服克拉屈滨最近公布了有前景的疗效数据。然而，需要权衡益处与风险，以确定这些化合物在当前治疗方案中的作用。在本综述中，讨论了一种有前景的化合物——口服克拉屈滨的疗效数据，并在上市后时代将其与已知和预期的风险进行权衡，最后展望了该药物未来在MS治疗算法中的潜在地位。
相似文献
1
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Drug Des Devel Ther. 2010 Jul 21;4:117-26. doi: 10.2147/dddt.s6627.
2
Oral therapy for multiple sclerosis--sea change or incremental step?
N Engl J Med. 2010 Feb 4;362(5):456-8. doi: 10.1056/NEJMe0912019. Epub 2010 Jan 20.
3
Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS.
Nat Rev Neurol. 2011 Jul 12;7(8):425-7. doi: 10.1038/nrneurol.2011.105.
4
New drugs may improve, complicate treatment for multiple sclerosis.
Nat Med. 2010 Mar;16(3):272. doi: 10.1038/nm0310-272.
5
Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
CNS Drugs. 2011 Aug;25(8):673-98. doi: 10.2165/11207350-000000000-00000.
6
Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
J Neurol Sci. 2011 Dec;311 Suppl 1:S29-34. doi: 10.1016/S0022-510X(11)70006-5.
7
Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
Eur J Clin Pharmacol. 2014 Mar;70(3):373-5. doi: 10.1007/s00228-013-1620-7. Epub 2013 Dec 6.
8
Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
Drugs Today (Barc). 2010 May;46(5):315-25. doi: 10.1358/dot.2010.46.5.1497556.
9
Fingolimod for relapsing multiple sclerosis: an update.
Expert Opin Pharmacother. 2010 May;11(7):1183-96. doi: 10.1517/14656561003769866.
10
Oral cladribine and fingolimod for relapsing multiple sclerosis.
N Engl J Med. 2010 May 6;362(18):1738; author reply 1739-40. doi: 10.1056/NEJMc1002550.
引用本文的文献
1
Multiple sclerosis: etiology in the context of neurovascular unit and immune system involvement and advancements with blood-brain barrier models.
Front Immunol. 2025 Jun 10;16:1595276. doi: 10.3389/fimmu.2025.1595276. eCollection 2025.
2
Cladribine tablets after treatment with natalizumab (CLADRINA) - rationale and design.
Ther Adv Neurol Disord. 2024 Apr 4;17:17562864241233858. doi: 10.1177/17562864241233858. eCollection 2024.
3
Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure.
Front Neurol. 2022 Mar 31;13:854390. doi: 10.3389/fneur.2022.854390. eCollection 2022.
4
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies.
Vaccines (Basel). 2021 Jan 28;9(2):99. doi: 10.3390/vaccines9020099.
5
Immunological Aspects of Approved MS Therapeutics.
Front Immunol. 2019 Jul 11;10:1564. doi: 10.3389/fimmu.2019.01564. eCollection 2019.
6
Interferon β-Mediated Protective Functions of Microglia in Central Nervous System Autoimmunity.
Int J Mol Sci. 2019 Jan 7;20(1):190. doi: 10.3390/ijms20010190.
本文引用的文献
1
Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
Expert Rev Neurother. 2010 Mar;10(3):365-75. doi: 10.1586/ern.10.12.
2
Impact of cladribine on soluble adhesion molecules in multiple sclerosis.
Acta Neurol Scand. 2010 Dec;122(6):409-13. doi: 10.1111/j.1600-0404.2010.01330.x.
3
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20.
4
Oral therapy for multiple sclerosis--sea change or incremental step?
N Engl J Med. 2010 Feb 4;362(5):456-8. doi: 10.1056/NEJMe0912019. Epub 2010 Jan 20.
5
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.
6
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.
7
Development of oral cladribine for the treatment of multiple sclerosis.
J Neurol. 2010 Feb;257(2):163-70. doi: 10.1007/s00415-009-5359-0.
8
Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
N Engl J Med. 2009 Sep 10;361(11):1081-7. doi: 10.1056/NEJMoa0810316.
9
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
N Engl J Med. 2009 Sep 10;361(11):1075-80. doi: 10.1056/NEJMoa0810257.
10
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2.
Zotero 插件